RAYDIAX receives 7.5 million euros

The MedTech spin-off RAYDIAX has raised a total of 7.5 million euros in funding to drive forward the clinical validation and market entry of its therapy assistance computer tomograph TACT. The funds will be used in particular for first-in-human studies, further development to series maturity and the establishment of sales, production and quality management.

Combination of venture capital and EU funding

Five million euros come from venture capital provided by existing business angels, bmp Ventures with the IBG funds and the newly invested GETEC Family Office led by Dr. Karl Gerhold

With the successful completion of our Series A1, we have reached a decisive milestone on the way to clinical application.

Dr. Thomas Hoffmann, CEO and co-founder of RAYDIAX

In addition, the company will receive 2.5 million euros in funding from the European Commission's EIC Accelerator, a central funding instrument for European deep-tech innovations with high scaling potential.

Transition from development to clinical application

RAYDIAX is a spin-off of the STIMULATE research campus at Otto von Guericke University Magdeburg and develops image-guided technologies for minimally invasive therapies.

With the funding, the clinical phase is now beginning: first-in-human studies are to generate evidence for the application of the system in humans for the first time. At the same time, the company is working on the industrialization of the product and is preparing the first commercial installations. This step marks the transition from technological development to regulatory approval and market scaling.

New device class for minimally invasive cancer therapies

The focus is on the TACT system, a specially developed therapy assistance CT for interventional oncology. Unlike conventional diagnostic scanners, the device supports the planning, execution and monitoring of minimally invasive procedures in an integrated workflow.

Minimally invasive cancer therapies are becoming increasingly important in view of ageing populations and rising cancer incidences. In many cases, they can shorten operating times, reduce the risk of complications and enable faster recovery. At the same time, clinical resources can be used more efficiently and additional treatment capacities can be created.

The TACT addresses a clearly defined clinical need in interventional oncology and has the potential to establish a new device category for minimally invasive cancer therapies.

Dr. Jan Alberti, Managing Partner at bmp Ventures

With TACT, RAYDIAX aims to significantly expand the range of applications for such procedures and establish a new product category in interventional radiology.

The system is based on focused CT live imaging, which is intended to accompany interventions more precisely. In addition to efficiency gains in medical procedures, the approach promises lower radiation exposure for patients and medical staff. A larger device aperture also enables new application scenarios, such as the integration of robotic assistance systems.

European funding underlines strategic relevance

The support from the EIC Accelerator is seen as a strong signal of the importance of the technology. The program is aimed specifically at companies that combine scientific excellence with market-oriented scaling.

With its innovative technology, RAYDIAX creates focused live CT imaging that reduces radiation exposure for patients and surgeons as well as surgery time.

Steffen Schmidt, CFO of the GETEC Group

With the current financing, RAYDIAX aims to translate its scientific basis into marketable medical technology and position itself internationally in the growing market for minimally invasive cancer therapies.